Prenatal screening service for fetal RHD genotyping to guide prophylaxis: the two-year experience of the Friuli Venezia Giulia region in Italy.
Blood transfusion · 01.03.2023 · 21 (2) · 93-99
DOI: 10.2450/2022.0004-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood transfusion, erschienen am 01.03.2023. Verfasst von Donatella Londero und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, ASUFC-Udine, Italy. Hauptthemen laut MEDLINE: Prenatal Diagnosis, Rh-Hr Blood-Group System. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Fetal RHD genotyping of cell-free fetal DNA (cff-DNA) from RhD-negative pregnant women can be used to guide anti-D prophylaxis: the knowledge of fetal RhD type can direct and restrict the use of prenatal anti-D immunoglobulin exclusively to RhD-negative women carrying a RhD-positive fetus. Since November 2019 in the region of Friuli Venezia Giulia (Italy) a prenatal screening service has been offered to RhD-negative women at 22-24 weeks of gestation. MATERIALS AND METHODS: The cff-DNA is extracted from a simple peripheral maternal blood sample to analyze the fetal RHD gene: the results are interpreted as RHD-positive fetus, RHD-negative fetus, or Inconclusive. The service is shared with all regional hospitals and tests are provided free of charge by the National Health System. RESULTS: Overall, 142 RhD-negative pregnant women were recruited in nearly 2 years. Fetal RHD genotyping was negative in 53 pregnancies and positive in 89 pregnancies. Thus, unnecessary treatment of pregnant women and exposure to a scarce plasma-derived medicinal product was avoided, by the use of a single blood sample, in 37.8% of cases, representing 100% of the RhD-negative women carrying a RhD-negative fetus in our cohort. DISCUSSION: week of gestation, during which prenatal prophylaxis is usually administered. Giving prenatal anti-D immunoglobulin exclusively to RhD-negative women carrying a RhD-positive fetus reduces the overall use of anti-D immunoglobulin, which is becoming an ever more limited resource. The high sensitivity of the procedure provides evidence that the implementation of a diagnostic test in a reference laboratory guarantees the quality of the results, the concordance of reports and the sustainability of costs, representing an excellent guide to targeted use of prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Transfusion Medicine, ASUFC-Udine, Italy.
Zitieren
APA
Londero, D., Merluzzi, S., Dreossi, C., & Barillari, G. (2023). Prenatal screening service for fetal RHD genotyping to guide prophylaxis: the two-year experience of the Friuli Venezia Giulia region in Italy. Blood transfusion, 21(2), 93-99. https://doi.org/10.2450/2022.0004-22
Vancouver
Londero D, Merluzzi S, Dreossi C, Barillari G. Prenatal screening service for fetal RHD genotyping to guide prophylaxis: the two-year experience of the Friuli Venezia Giulia region in Italy. Blood transfusion. 2023;21(2):93-99. doi:10.2450/2022.0004-22
BibTeX
@article{Londero2023,
author = {Londero, Donatella and Merluzzi, Sonia and Dreossi, Cristina and Barillari, Giovanni},
title = {Prenatal screening service for fetal RHD genotyping to guide prophylaxis: the two-year experience of the Friuli Venezia Giulia region in Italy},
journal = {Blood transfusion},
year = {2023},
volume = {21},
number = {2},
pages = {93--99},
doi = {10.2450/2022.0004-22}
}
EUVIMED